Bevacizumab in heavily pre-treated ovarien cancer pations and the predictive value of serum VEGF

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsResearch

Original languageEnglish
Title of host publicationAbstracts
PublisherEuropean Cancer Organization (ECCO)
Publication date2009
Publication statusPublished - 2009
EventECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology) - Berlin, Germany
Duration: 20. Sep 200924. Sep 2009

Conference

ConferenceECCO 15-ESMO34 (ECCO - the European Cancer Organisation - ESMO - the European Society for Medical Oncology)
CountryGermany
CityBerlin
Period20/09/200924/09/2009

Cite this

@inbook{937ddee0aced11de9743000ea68e967b,
title = "Bevacizumab in heavily pre-treated ovarien cancer pations and the predictive value of serum VEGF",
author = "Maja Smerdel and {Dahl Steffensen}, Karina and Marianne Waldstr{\o}m and Ivan Brandslund and Anders Jakobsen",
year = "2009",
language = "English",
booktitle = "Abstracts",
publisher = "European Cancer Organization (ECCO)",

}

Bevacizumab in heavily pre-treated ovarien cancer pations and the predictive value of serum VEGF. / Smerdel, Maja; Dahl Steffensen, Karina; Waldstrøm, Marianne; Brandslund, Ivan; Jakobsen, Anders.

Abstracts. European Cancer Organization (ECCO), 2009.

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsResearch

TY - ABST

T1 - Bevacizumab in heavily pre-treated ovarien cancer pations and the predictive value of serum VEGF

AU - Smerdel, Maja

AU - Dahl Steffensen, Karina

AU - Waldstrøm, Marianne

AU - Brandslund, Ivan

AU - Jakobsen, Anders

PY - 2009

Y1 - 2009

M3 - Conference abstract in proceedings

BT - Abstracts

PB - European Cancer Organization (ECCO)

ER -